SWA
ITCI

SFMG Wealth Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

SFMG Wealth Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,748
Closed -$231K – 303
2025
Q1 		$231K Buy
+1,748
New +$218K 0.02% 241

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SFMG Wealth Advisors's ITCI Position: Q2 2025 in Review

SFMG Wealth Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,748 shares — an estimated $231K sold.

SFMG Wealth Advisors first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $231K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • SFMG Wealth Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • SFMG Wealth Advisors sold 1,748 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $231K.
  • SFMG Wealth Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
  • SFMG Wealth Advisors's Intra-Cellular Therapies Inc. position peaked at $231K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on SFMG Wealth Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.